Publication | Open Access

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Diabetes ManagementSustain 1DiabetesType 2Clinical TrialsMulticentre Phase 3ATreatment OptionPharmacotherapyDiabetes MellitusMedicine